
ImmunityBio gains exclusive U.S. rights to Tokyo-172 BCG for bladder cancer after positive Phase 3 trial.
ImmunityBio secured exclusive U.S. development and supply rights for the Tokyo-172 strain of BCG, an investigational bladder cancer therapy not yet FDA-approved. This follows positive Phase 3 trial results showing Tokyo-172 BCG is as effective as the...


